{"id":"W3133746780","doi":"10.1016/s0140-6736(21)00213-0","title":"Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1302,"is_retracted":false,"has_abstract":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Placebo; Overweight; Type 2 diabetes; Internal medicine; Body mass index; Diabetes mellitus; Randomized controlled trial; Glycated hemoglobin; Physical therapy; Endocrinology; Liraglutide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03487184394042082,"score_gpt":0.2963627505833139,"score_spread":0.2614909066428931,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}